RecruitingNot applicableNCT06855706
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
Studying Malignant tumor of fallopian tubes
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Roswell Park Cancer Institute
- Principal Investigator
- Emese ZsirosRoswell Park Cancer Institute
- Intervention
- Behavioral Intervention(behavioral)
- Enrollment
- 120 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- Roswell Park Cancer Institute, Buffalo, New York, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06855706 on ClinicalTrials.govOther trials for Malignant tumor of fallopian tubes
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07278336A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian CancerAbbVie
- RECRUITINGPHASE2NCT06787612Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRegeneron Pharmaceuticals
- RECRUITINGPHASE2NCT05887609An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and OlaparibUniversity of Colorado, Denver
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT05053750TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerM.D. Anderson Cancer Center